Guenther Koehne, MD

Marcio Fagundes, M.D., is a Board-certified radiation oncologist with Miami Cancer Institute, a part of Baptist Health South Florida. He has extensive experience in proton therapy - the most advanced cancer treatment in the world – and has conducted significant research. Dr. Fagundes has presented research results showing the advantages of proton therapy for prostate cancer, breast cancer and head and neck cancer at numerous meetings of the Particle Therapy Co-Operative Group and the American Society of Therapeutic Radiation Oncologists – two professional associations to which he belongs. He also has published dozens of articles in peer reviewed journals, including Journal of Clinical Oncology, International Journal of Particle Therapy and International Journal of Radiation Oncology. Dr. Fagundes received his medical degree from Universidade Federal do Rio Grande do Sul in Porto Alegre, Brazil, and completed a radiation oncology residency at the University of Miami Miller School of Medicine/Jackson Memorial Hospital – Sylvester Comprehensive Cancer Center. He also completed a fellowship in radiation oncology at Harvard Medical School, Massachusetts General Hospital, in Boston. He gained teaching experience as an assistant professor of radiation oncology at Tufts University School of Medicine in Boston, and currently trains his peers on an innovative treatment protocol for prostate cancer. Before joining Miami Cancer Institute, Dr. Fagundes was medical director of the Provision Center for Proton Therapy in Knoxville, Tennessee.

Murugesan Manoharan, M.D., FRACS, is a surgical urologic oncologist and the chief of urologic oncology surgery at Miami Cancer Institute. Dr. Manoharan specializes in the treatment of genitourinary cancers, including bladder, kidney, prostate and testicular cancer. Dr. Manoharan also serves as the chairman of the Department of Urology at Baptist Health South Florida and a professor of urology at Herbert Wertheim College of Medicine, Florida International University.In 2022, the Abbhi Family Endowed Chair in Urologic Oncology was created to help Dr. Manoharan and the Institute conduct research and clinical trials to improve survival rates and quality of life for patients with bladder cancer.He joined Miami Cancer Institute from the Sylvester Comprehensive Cancer Center, where he served as one of the site disease group leaders for genitourinary cancers. He also practiced urology at Jackson Memorial Hospital and the Veterans Affairs Medical Center in Miami.Dr. Manoharan is a renowned leader in the treatment of prostate cancer, kidney cancer, bladder cancer and other urologic malignancies. He is an expert in minimally invasive surgery, including nerve sparing robotic prostatectomy, robotic kidney surgery, robotic bladder removal and neobladder reconstruction. Dr. Manoharan was one of the first urologists in the United States to perform robotic bladder removal surgery and reconstruction of neobladder using a Pfannenstiel incision. He also specializes in other minimally invasive ablative cancer procedures, such as high-intensity focused ultrasound (HIFU) therapy, cryotherapy and the NanoKnife procedure to treat prostate cancer. He has extensive experience training medical students, residents and oncology fellows. He has won numerous awards for his teaching and clinical excellence, as well as his research work. Dr. Manoharan’s research interests include stem cell applications, biomarkers and cancer outcomes. He serves as an editorial reviewer for several scientific publications. He is also widely published in peer-reviewed medical journals and is an invited speaker at national and international scientific symposiums. Dr. Manoharan has authored more than 140 scientific articles and 15 textbook chapters and has presented papers and posters at more than 100 national and international meetings. He served as vice chairman and a member of the International Bladder Cancer Guidelines committee, organized by the WHO and Société Internationale d'Urologie.When he is not treating patients, Dr. Manoharan enjoys music and traveling.

Rohan Garje, M.D., is a nationally renowned medical oncologist and the chief of genitourinary medical oncology at Miami Cancer Institute. Dr. Garje specializes in the treatment of prostate, kidney, bladder, testicular and penile cancer. Dr Garje has significant expertise in the design of novel investigator-initiated clinical trials and has served as the principal investigator for numerous phase I, II and III clinical trials. He focuses on providing precision oncology care utilizing targeted therapy, hormonal therapy, immunotherapy, radioligand therapy and chemotherapy. Dr. Garje is an internationally published leader in cancer research. He has amassed over 30 publications in prestigious journals, such as Journal of Clinical Oncology and the Journal of Immunotherapy for Cancer. At the Institute, he leads a team of medical oncologists actively involved in clinical research bringing industry-leading treatments to patients with genitourinary cancers. Before joining Miami Cancer Institute in 2022, Dr. Garje served as an associate professor of medicine in hematology and oncology at the University of Iowa/Holden Comprehensive Cancer Center.Dr. Garje is also the chair for the castration-resistant prostate cancer guidelines committee for the American Society of Clinical Oncology. He leads the committee's work in reviewing research and writing guidelines for prostate cancer treatment. Dr. Garje serves on the editorial board for Current Problems in Cancer and is a reviewer for multiple journals including Journal of Clinical Oncology and Journal of Oncology Practice. Dr. Garje is passionate about providing individual care to each patient because each has a unique journey. He takes time to listen to patients and walks with them throughout their treatment. When he is not treating patients, Dr. Garje enjoys spending time with his family and traveling, always with a camera in hand. He is fluent in English, Hindi, Telugu and Marathi.